R&D Intensity
R&D Intensity measures research and development expenditure as a percentage of revenue, indicating how heavily a company invests in innovation and future product pipelines — a critical metric in Indian pharmaceuticals and information technology.
Research and development spend represents the seed capital of future competitive advantage. A company with high R&D intensity is betting that tomorrow's revenue streams depend on today's intellectual investment. The ratio — R&D expense divided by net revenue — allows comparison across companies and over time, revealing whether innovation investment is expanding, stable, or being harvested.
In Indian pharmaceuticals, R&D intensity is a closely watched indicator of the transition from commodity generics to complex generics, biosimilars, or novel drug discovery. Sun Pharmaceutical historically spent 8–10 per cent of net sales on R&D during its buildout of specialty pipeline products targeting dermatology and oncology in the US market. Dr Reddy's Laboratories and Lupin pursued parallel strategies, and their R&D intensity trajectories were tracked as proxies for pipeline maturity and future product launch potential.
For IT services companies, R&D — often reclassified as 'innovation investment' or 'digital capability building' — tends to be lower as a percentage of revenue because the primary input is human capital rather than laboratory equipment. However, product-oriented tech companies such as Mphasis or Persistent Systems, which develop IP-led solutions, carry meaningful R&D ratios that differentiate them from pure service providers.
Under Ind AS, R&D expenditure is split: research phase costs are expensed immediately, while development phase costs meeting specific criteria — technical feasibility, intention to complete, ability to use or sell, and probable economic benefit — may be capitalised as intangible assets. This creates a divergence between cash R&D spend and P&L-reported R&D expense. Analysts tracking cash R&D from the cash flow statement alongside disclosed capitalisation policies gain a truer picture of investment intensity.
Tax incentives significantly affect R&D decisions in India. Section 35(2AB) of the Income Tax Act historically provided weighted deductions — at 150 to 200 per cent — for in-house R&D expenditure by approved companies, meaning after-tax R&D cost was meaningfully below pre-tax spend. Changes to this provision over the years affected the economics of R&D investment for smaller pharma and chemical companies.
A company that cuts R&D intensity sharply to defend near-term margins is essentially mortgaging future competitive position. This trade-off is visible in pharma companies facing generic erosion in the US: maintaining R&D intensity despite revenue pressure is a signal of long-term orientation, while slashing it is a warning that near-term financial engineering may come at the cost of the pipeline.